Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $39.00 Consensus Target Price from Analysts

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have been given an average recommendation of “Moderate Buy” by the six research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $39.00.

ARTV has been the topic of several research reports. Needham & Company LLC restated a “buy” rating and issued a $41.00 price target on shares of Artiva Biotherapeutics in a report on Monday, June 8th. Wedbush boosted their price objective on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Wall Street Zen downgraded shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. Finally, HC Wainwright raised their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, May 8th.

Insider Transactions at Artiva Biotherapeutics

In other news, SVP Heather Raymon sold 3,095 shares of the stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total value of $27,885.95. Following the completion of the sale, the senior vice president owned 148,228 shares in the company, valued at approximately $1,335,534.28. This trade represents a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ra Capital Management, L.P. bought 31,000 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were bought at an average price of $8.88 per share, for a total transaction of $275,280.00. Following the completion of the acquisition, the director owned 16,794,043 shares in the company, valued at approximately $149,131,101.84. This trade represents a 0.18% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders acquired 9,534,631 shares of company stock worth $104,042,163 and sold 53,040 shares worth $477,890. 21.40% of the stock is currently owned by company insiders.

Institutional Trading of Artiva Biotherapeutics

Large investors have recently bought and sold shares of the company. Marshall Wace LLP purchased a new stake in shares of Artiva Biotherapeutics during the second quarter valued at approximately $79,000. Qube Research & Technologies Ltd acquired a new position in shares of Artiva Biotherapeutics during the second quarter worth $58,000. Jane Street Group LLC purchased a new position in shares of Artiva Biotherapeutics in the second quarter valued at $67,000. Bridgeway Capital Management LLC purchased a new position in shares of Artiva Biotherapeutics in the second quarter valued at $53,000. Finally, BNP Paribas Financial Markets grew its holdings in Artiva Biotherapeutics by 14,463.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after purchasing an additional 117,733 shares in the last quarter.

Artiva Biotherapeutics Trading Up 1.1%

Shares of ARTV opened at $9.41 on Friday. The firm has a market capitalization of $232.62 million, a P/E ratio of -2.66 and a beta of 2.18. The stock’s fifty day simple moving average is $9.04 and its 200 day simple moving average is $6.92. Artiva Biotherapeutics has a twelve month low of $1.71 and a twelve month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Sell-side analysts predict that Artiva Biotherapeutics will post -2.45 earnings per share for the current year.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.